Immatics (IMTX) Non-Current Assets (2019 - 2025)
Immatics (IMTX) posted Non-Current Assets of $67.9 million for Q4 2025, down 4.06% sequentially from $70.8 million in Q3 2025, and down 4.58% YoY from $71.2 million in Q4 2024.
Immatics (IMTX) Non-Current Assets (2019 - 2025) Analysis & Trends
Immatics has reported Non-Current Assets for 7 years, with the latest figure at $67.9 million in Q4 2025.
- Quarterly Non-Current Assets fell 4.58% year-over-year to $67.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $67.9 million (down 4.58% YoY) and the FY2025 annual result came in at $65.9 million, down 8.57% from the prior year.
- Non-Current Assets eased to $67.9 million in Q4 2025 per IMTX's latest filing, from $70.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $73.1 million in Q2 2024 and troughed at $19.0 million in Q1 2021.
- A 5-year average of $49.3 million and a median of $53.4 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets soared 108.38% in 2023, then declined 4.58% in 2025.
- Over 5 years, Non-Current Assets stood at $25.7 million in 2021, then grew by 21.88% to $31.3 million in 2022, then jumped by 108.38% to $65.2 million in 2023, then increased by 9.15% to $71.2 million in 2024, then dropped by 4.58% to $67.9 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $67.9 million, $70.8 million, and $71.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | 67.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 67.90 Mn |
| Sep 30, 2025 | 70.77 Mn |
| Jun 30, 2025 | 71.73 Mn |
| Mar 31, 2025 | 71.66 Mn |
| Dec 31, 2024 | 71.16 Mn |
| Sep 30, 2024 | 70.79 Mn |
| Jun 30, 2024 | 73.07 Mn |
| Mar 31, 2024 | 70.32 Mn |
| Dec 31, 2023 | 65.20 Mn |
| Sep 30, 2023 | 57.09 Mn |
| Jun 30, 2023 | 49.62 Mn |
| Mar 31, 2023 | 35.89 Mn |
| Dec 31, 2022 | 31.29 Mn |
| Sep 30, 2022 | 32.25 Mn |
| Jun 30, 2022 | 34.44 Mn |
| Mar 31, 2022 | 24.99 Mn |
| Dec 31, 2021 | 25.67 Mn |
| Sep 30, 2021 | 22.14 Mn |
| Jun 30, 2021 | 21.88 Mn |
| Mar 31, 2021 | 19.03 Mn |